Stock Markets July 24, 2026 12:31 PM

Surgery Partners to Sell Two Idaho Falls Hospitals in $1.15 Billion Transaction

Deal expected to deliver about $795 million to Surgery Partners; closing contingent on multiple approvals and regulatory clearances

By Nina Shah
Share
Twitter Reddit Facebook LinkedIn
SGRY

Surgery Partners Inc said it has reached an agreement to sell its ownership interests in Mountain View Hospital and Idaho Falls Community Hospital to Intermountain Health for roughly $1.15 billion. The company will receive approximately $795 million in total consideration, with substantial cash proceeds expected at closing subject to customary purchase price adjustments. Completion requires several internal and regulatory approvals and the company reaffirmed its 2026 outlook excluding the impact of the transaction.

Surgery Partners to Sell Two Idaho Falls Hospitals in $1.15 Billion Transaction
SGRY
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Surgery Partners agreed to sell ownership interests in Mountain View Hospital and Idaho Falls Community Hospital to Intermountain Health for approximately $1.15 billion; Surgery Partners' portion of the consideration is about $795 million.
  • Closing is subject to internal approvals, execution of binding Securities Purchase Agreements, Hart-Scott-Rodino waiting period expiration, material regulatory approvals and certain third-party consents.
  • Surgery Partners reaffirmed its 2026 outlook excluding the transaction, forecasting revenues of $3.35 billion to $3.45 billion and Adjusted EBITDA of at least $530 million.

Surgery Partners Inc saw its shares rise 5.8% on Friday after the company announced an agreement to divest its ownership interests in two Idaho Falls hospitals to Intermountain Health for approximately $1.15 billion.

Under the terms disclosed, Surgery Partners will receive total consideration of about $795 million for its stakes in Mountain View Hospital and Idaho Falls Community Hospital. The company said it expects to realize substantial cash proceeds when the transaction closes, with the final cash amount subject to customary purchase price adjustments.

The sale remains subject to a range of approvals and closing conditions. Among the required steps are approvals from Mountain View Hospital physician members and its physician governing board and the execution of binding Securities Purchase Agreements. The transaction also depends on the expiration of any applicable waiting periods under the Hart-Scott-Rodino Act, the receipt of material regulatory approvals and certain third-party consents.

Surgery Partners will maintain its ongoing partnership with Intermountain Health following the transaction. The company also emphasized that physician ownership of Mountain View Hospital will remain unchanged as part of the arrangement. Management expects the deal to close in the coming months, conditioned on securing the necessary approvals and consents.

Chief Executive Officer Eric Evans characterized the disposition as the largest single move in the company’s portfolio optimization plan. According to the company, the transaction is intended to simplify operations and better position Surgery Partners to accelerate momentum in the ambulatory surgery center space.

The company also confirmed its previously stated 2026 outlook on a basis that excludes the impact of the hospital sale. Revenues are still expected to be in a range of $3.35 billion to $3.45 billion, and Adjusted EBITDA is projected to be at least $530 million. Surgery Partners said it will disclose more detail about how the transaction is expected to affect its 2026 financial outlook at the appropriate time, once the deal is completed.

Investors can also note that Surgery Partners is scheduled to report second quarter 2026 results on Monday, August 10, 2026.


Key points

  • Surgery Partners agreed to sell two Idaho Falls hospitals to Intermountain Health for approximately $1.15 billion, with about $795 million of consideration attributable to Surgery Partners.
  • The deal requires multiple internal approvals, binding sale agreements, Hart-Scott-Rodino waiting period expiration, material regulatory approvals and third-party consents before it can close.
  • Management reaffirmed its 2026 guidance excluding the transaction, with revenue guidance of $3.35 billion to $3.45 billion and Adjusted EBITDA of at least $530 million.

Sectors impacted - Healthcare providers, hospital operations, and outpatient/ambulatory surgery center markets may be affected by the portfolio change and subsequent strategic focus.


Risks and uncertainties

  • Regulatory and antitrust clearances - The transaction depends on expiration of Hart-Scott-Rodino waiting periods and receipt of material regulatory approvals, any of which could delay or prevent closing. (Impacts regulatory and healthcare sectors)
  • Third-party and internal approvals - Completion requires physician member and governing board approvals at Mountain View Hospital, execution of binding agreements and certain third-party consents, all of which introduce execution risk. (Impacts hospital governance and transaction certainty)
  • Final consideration adjustments - The approximate $795 million cash consideration is subject to customary purchase price adjustments, meaning the ultimate cash proceeds at closing could differ from current estimates. (Impacts Surgery Partners’ balance sheet and liquidity planning)

This report presents the details of the announced agreement and the company disclosures related to the expected timing, approvals and financial guidance. No additional projections or outcomes beyond the company statements have been included.

Risks

  • Regulatory and antitrust approvals must be obtained before closing, which could delay or prevent the transaction.
  • Required internal approvals and third-party consents introduce execution risk for completing the sale.
  • The approximately $795 million in consideration to Surgery Partners is subject to customary purchase price adjustments, so final cash proceeds may change.

More from Stock Markets

Anthropic debuts Claude Opus 5 as lower-cost option for workplace AI tasks Jul 24, 2026 Meta AI Expands Assistant Capabilities with Planning, Calendar and App Integration Jul 24, 2026 Anthropic Debuts Opus 5, Promising Fable 5-Like Performance at Lower Cost Jul 24, 2026 Meta expands Meta AI with autonomous task capabilities and launches Seller app Jul 24, 2026 Blackstone, Donerail and Centerbridge Emerged as Final Bidders for MarineMax Jul 24, 2026